Category Archives: Therapies

Pharma R&D and patient advocacy to discuss patient involvement in clinical research at Patients as Partners® Europe 2024

NEW YORK, NY, United States, 12-Mar-2024 — /EPR HEALTHCARE NEWS/ — The Conference Forum today announced the launch of the 8th annual Patients as Partners® Europe meeting, taking place May 14-15, 2024, at Plaisterers’ Hall, in London, England. Patients as Partners® Europe offers an unparalleled opportunity to hear from pharma R&D and patient advocacy on how patient involvement gets done to drive greater efficiencies and inclusivity in clinical research with better outcomes.

“Patients as Partners Europe brings advocates and sponsors together in a unique forum focused on improving collaborations that result in meaningful impact for patients,” said 2024 co-chair, Victoria DiBiaso, MPH, Global Head, Patient Informed Development & Health Value Translation, Sanofi.

The 2024 keynotes and featured speakers include:

  • Patient Advocate Keynote Derek Stewart, OBE on understanding mental health support in clinical research
  • Patient Advocate Keynote Sarah Zenner Dolan, a former biotech executive on navigating clinical trials as a patient
  • GSK’s Andrew Garvey, Global Patient Advocacy Lead, on what has been working, and what has not, in GSK’s effort to advance patient engagement in clinical trials
  • Pfizer’s Patrick Gallogly, Medical Advisor, Pfizer, on the learnings generated from an industry-first LGBTQ+ oncology advisory board
  • Lundbeck’s Anders Lassen, Senior Director, Patient Insights, on using patient-centric integrated evidence approaches to inform drug development decisions
  • Boehringer Ingelheim’s Annie Gilbert, Global Patient Advocacy Lead, on the pilot program bridging the communication gap by sending trial updates to patients
  • Ipsen’s Oleksandr Gorbenko,​​​​​​​ Global Patient Affairs Director, Neurosciences, on how Ipsen partnered with patient advocacy to create robust patient experience mapping
  • AstraZeneca’s Lisa Kerr, Senior Director, R&D Patient Science, on creating a measurement strategy and business investment case to scale patient-centric R&D approaches
  • Astellas’ Stephen Head, Senior Director, Patient Partnerships, on instilling conscious awareness of the patient into everyday work practices
  • Prostate Cancer Research’s David James, Director of Patient Projects, on demystifying and diversifying clinical trials to engage underserved communities

“Patients as Partners® Europe presents case examples on how patient involvement in clinical research can accelerate medicine development, how it can improve better access, inclusivity and diversity,” said Valerie Bowling, Executive Director.

Key topics to be addressed include:

  • ​​​​The future of patient-informed research
  • Understanding patient preferences in decentralized clinical trials
  • Advancing health equity and diversifying clinical trials to engage underserved communities
  • The patient experience data landscape and returning patient data
  • Turning patient insights into action
  • Mapping and measuring patient engagement
  • Patient burden-reducing solutions and technologies
  • Regulatory requirements and patient engagement in drug development

The 2024 meeting is co-chaired by ​​​​​​​Sanofi’s Victoria DiBiaso, MPH, Global Head, Patient Informed Development & Health Value Translation; Patient Advocate, ​​​​​​​​​​​​​​Alfred Samuels; and Parexel’s Rosamund Round, VP, Patient Engagement.

About Patients as Partners® Europe:
Patients as Partners® Europe is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement, access and diversity across the entire clinical development continuum. To learn more about Patients as Partners and access the full agenda, visit PatientsAsPartnersEU.com.

About the Conference Forum:
The Conference Forum is a life science industry research, conference development and marketing firm. The company brings the full spectrum of executives together to share ideas and information on how to advance efficient medicine development and delivery, patient diversity and access. They produce trusted conferences, webinars, podcasts, digital editorial and provide marketing services. To learn more, visit theconferenceforum.org.

SOURCE: EuropaWire

First patient enrolled in an international multicenter clinical study for non-invasive cardiac resynchronization therapy

BOLZANO/ BOZEN, Italy, 19-Mar-2023 — /EPR HEALTHCARE NEWS/ — XSpline SPA, a start-up company incorporated in Bolzano (Italy) and the Ordensklinikum Linz Elisabethinen Hospital in Linz (Austria) today announced the first patient enrolled in a clinical study (ClinicalTrials.govID: NCT05327062) for the cardiac resynchronization therapy (CRT) guided by non-invasive electrical and venous anatomy assessment.  The international multicenter prospective study will include 150 patients from 16 centers in the U.S. and Europe.

XSpline Cloud provides a cloud-based non-invasive cardiac panoramic mapping technology to select individual CRT treatment strategy and predict outcomes.

Fast and fully automatic Artificial Intelligence based epi- and endocardial segmentation of cardiac structures, including coronary sinus veins, provides clear understanding of individual patient’s anatomy. The electrical assessment is based on a 3D panoramic electro-anatomical map based on 12 -lead ECG only, without requiring multichannel ECG recording or any kind of body surface potential mapping. XSpline Cloud is the first system in the world with AI based identification of the correct target zone for LV lead implantation.

The cloud-platform guarantees full operability with existing clinical standards and data formats; it supports IHE profiles, HL7 FIHR, DICOM, and a broad range of ECG formats. The platform also provides embedded medical grade visualization tools, such as an integrated multimodality DICOM viewer, an ECG viewer with measurement capabilities, a high-performance 3D viewer for segmented cardiac structures and electro- anatomical maps as well as an interactive navigator for LV lead placement.

Dr. Georgios Kollias, M.D., is the principal investigator for the clinical trial in Austria and performed the first procedure on a 71-year-old patient with ESV LV of 154 ml and EF LV of 20%.

“The XSpline Cloud software provides a unique approach to selecting an individualized CRT treatment strategy. It is a comprehensive tool for successful CRT implantation that can also predict outcomes, making the implantation procedure faster, easier, and safer for the patient. We are very pleased to start using this tool in our clinic”, said Dr. Kollias.

“XSpline SPA is supported by an international R&D team of skilled clinicians, mathematicians, and biomedical engineers with the shared goal of improving patient care. We think that the real-time visualization of each patient’s individual anatomy, the precise non-invasive electro-anatomical endo- and epicardial activation map and the interactive navigator will help to increase CRT responders”, said Mr. Werner Rainer, CEO of the company.

XSpline Cloud is an investigational device and not yet approved for commercial use.

SOURCE: EuropaWire

MIGUN LIFE, the original brand of K healthcare, to participate at CES 2023

SEOUL, Korea, 20-Dec-2022 — /EPR HEALTHCARE NEWS/ — MIGUN LIFE (CEO Jacob Hun Cheol Chang), the originator of home medical appliance, will participate in CES 2023 world’s largest exhibition of home appliances which will be held on January at Las Vegas Convention Center in USA, and will unveil year 2023 new products.

MIGUN LIFE set up exhibition booth in Convention Center at Venetian Expo Hall and will introduce MIGUN LIFE’s products and brand to global buyers. The year 2023 new products to be unveiled this time are Re:ach RH01 and Re:ach RH02.

Product Information

Re:ach RH01 is product in a form of mat that allows us to enjoy relaxation and spine treatment. Re:ach RH02 is product in a form of mattress that allows us to enjoy both sleeping and spinal treatment which looks like a regular bed. The main feature of these products is that hidden jade massager comes out and starts spinal massage from one’s neck to hip. More than 10 acupressure rods stimulate blood spots exactly next to spine line. Once the operation is stopped, jade and acupressure rods return to inside of the mat or mattress, then you can have comfortable relaxation and sleep. Each product has leg cuffs exclusively for lower body which has functions for massaging legs and acupressure for soles of the foot. Also, they are evenly equipped with all convenient functions necessary for massage and relaxation such as thermal function, body scanning function, massage function tailored to individual’s body shape, intensity modulation massage function, relaxing music.

Personal thermal therapy appliance which was upgraded through MIGUN LIFE’s unrivaled technology Re:borne, personal ultrasound stimulating appliance Re:vive, high-frequency foot stimulator DAY:RE, these 3 products will be also exhibited.

Exhibition Booth

In the booth, products are placed in relaxed space so that visitors can experience the products comfortably and reception space for business talk are prepared separately. Furthermore, key component which shows MIGUN’s advanced technology, 2 sets of 5 thermo jades (10 thermo jades) will be exhibited with an emphasis on visitors to experience and understand MIGUN LIFE. 2 sets of 5 thermo jades (10 thermo jades) are made of 10 processed natural jades which have thermal function and it moves along the spine line and provides compression and heat.

Purpose of Participation

MIGUN LIFE has purpose to achieve from participating CES 2023. First of all, it is to promote brand and products worldwide to expand our global business in earnest from 2023 which we established 50 countries and for about 30 years. Also, it is to increase sales across the US since the establishment of US corporation in 2000. MIGUN LIFE has export record more than 5 million US dollars in the US, proceeded FDA (Food AND Drug Administration) for approval but also clinical trial at UC Irvine in the US. It explains that if MIGUN LIFE meets demand from American customers, the products will be recognized as differentiated product by going beyond global standards.

An official from MIGUN LIFE said “MIGUN LIFE, the original brand of K-healthcare, will participate CES 2023 to introduce 2023 new products and is asking for interest of MIGUN LIFE’s active role in Korea market but also in global market as well”

Homepage : http://www.migunlife.co.kr
Inquiry : +82-2-6951-2886 / Sales Rep: Andrew Yoon (migunlife_gsales@migunlife.co.kr)
Sales Rep: Andrew Yoon (migunlife_gsales@migunlife.co.kr)

SOURCE: EuropaWire

Exopharm: exosomes seen as an alternative to lipid nanoparticles (LNPs) and adeno-associated viral vectors (#AAVs) for targeted multi-dose delivery of modern medicines and vaccines

MELBOURNE, Australia, 3-Feb-2022 — /EPR HEALTHCARE NEWS/ — Australian technologist Dr Ian Dixon founded Exopharm in 2013 with the vision to harness the unique properties of exosomes as a new class of medicine. Dixon’s decisive early entry into exosome therapeutics is now bearing fruits.

Less than 10 years after its founding, Exopharm possesses a granted US patent for its key exosome manufacturing technology, LEAP™, and has run successful first-in-human clinical trials demonstrating the safety of its exosome products.

Exosomes have the potential to revolutionise medicine in many areas, including delivery of gene therapies into cell nucleus for rare and common genetic disorders, improving therapeutic window of small and large molecules by cell targeting, and by selective cellular delivery of next-generation DNA/RNA products.

In 2022, excitement around exosomes has converged on exosomes as an alternative to lipid nanoparticles (LNPs) and adeno-associated viral vectors (AAVs) for targeted multi-dose delivery of modern medicines and vaccines. Drug delivery accounts for a significant slice of the global pharmaceutical industry spend –around US$160b p.a. and growing strongly – and exosomes represent nature’s way to deliver a bioactive cargo into cells efficiently and safely.

Primed for growth

Dixon’s establishment of a specialist exosome medicines company has been followed by US based Codiak Biociences in 2015 (established by Arch Ventures) and Oxford based Evox Therapeutics in 2016. Today, only two dedicated exosome companies are listed on the public markets: Codiak (NASDAQ: CDAK) with a market cap of around US$200m; and Exopharm (ASX: EX1) with a market cap of around A$73m at the time of writing this article.

The field of exosome medicines is attracting the attention of financiers and pharmaceutical industry leaders. In late 2021, multinational pharmaceutical manufacturing services company Lonza jumped into exosome manufacture, a sign that they see big things over the horizon.

Over the past 9 years, Exopharm has grown and evolved but remains true to Dixon’s vision of exosome medicine development. The company now employs around 40 people most in its Melbourne, Australia, facility. Exopharm has built a toolbox of exosome technologies and knowhow which, in addition to the LEAP™ scalable exosome manufacturing platform, includes exosome analytical tools (Exoria) and technologies to load exosomes with a specific therapeutic cargo (LOAD) and target exosomes to select cells (EVPS).

Our business development team is attracting the attention of similar innovative biopharmaceutical and biomanufacturing companies, and validating the Exopharm technologies via collaboration research agreements.

Exopharm is not simply a technology company, however. Exopharm is pursuing a pipeline driven platform technology strategy, on the way to generating a revenue stream from technology out-licensing while developing its own exosome medicines for selected markets. More news on its pipeline products is expected to be ready for release later in CY ’22.

The Exopharm team has grown and changed to becoming more international in focus, improving on messaging and communications with the wider pharmaceutical industry. In 2021 Dr Jenn King joined the Board of Exopharm, bringing a wealth of big pharma and US biotech experience with her.

In 2022 we look to engage with more experts, as members of our advisory panels, as consultants, executives or Key Opinion Leaders. Please reach out to us if you want to be part of our vision.

At the company’s 10-year anniversary in late 2023, Exopharm will be a key part of the exosome medicines revolution.

SOURCE: EuropaWire

The biggest dedicated CBD & medical cannabis event in Europe takes place online between 28 and 30 April

LONDON, 21-Apr-2021 — /EPR HEALTHCARE NEWS/ — The CANNAVIST, the UK & Ireland’s essential guide to CBD & medical cannabis, presents CBD Live Europe, the biggest dedicated CBD & medical cannabis event to focus on the European hemp & CBD community this year. This free, virtual event takes place April 28-30.

CBD Live Europe follows the success of two similar events held by the publication in 2020. The virtual exhibition complete with an online auditorium is for consumers, patients, cannabis advocates, and business professionals across the continent.

An online exhibition hall will welcome more than 100 CBD brands, distributors and manufacturers while the auditorium will present three days of live educational material.

Day 1 will see Europe’s leading industry professionals take to the stage on pivotal issues including the post-pandemic hemp sector, regulation, FMCG and the importance of technology in unlocking the potential of cannabis.

Among the speakers to dominate on the B2B day will be Tim Phillips, founder of market intelligence firm CBD-Intel, Catherine Wilson, VP of the European Industrial Hemp Association and the co-founders of the world’s first CBD and hemp exchange, CanXchange.

Day 2 will welcome clinicians, researchers, founders and patients as Europe’s leading medical cannabis advocates share their experience and knowledge.

The line up for this medical cannabis and advocacy themed day will feature representatives from the European Cannabis Advocacy Network and high-profile campaigners, Charlotte & Billy Caldwell.

Day 3 will see a combination of CBD content aimed at health & wellbeing and personal growth goals.

From ‘How to launch your own CBD brand’ to our ‘Rewind, Reset & Reconnect’ online guided meditation, day 3 will focus the mind to end the week on a high note.

A total of 40 speakers will take over the auditorium at CBD Live Europe.

The event will take place entirely online at no cost to visitors to maximise this learning opportunity and make cannabis education more accessible. Those with an interest in CBD & medical cannabis from around the world are invited to log on for free.

CBD Live Europe will be live on virtual exhibition platform, VOXPO Events. In registering for CBD Live Europe, visitors will automatically be entered into a draw for a chance to win €500 worth of CBD goodies.

Visit voxpo-event.com to register. Visit this link to view the CBD Live Europe Auditorium Line Up.

SOURCE: EuropaWire

URSAPHARM and CEBINA collaborating to repurpose the antihistamine drug azelastine hydrochloride as a potential anti-SARS-CoV-2 therapeutic

SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EPR HEALTHCARE NEWS/ — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

With this goal in mind, URSAPHARM Arzneimittel GmbH, based in Saarbrücken, and the Vienna-based biotech company CEBINA GmbH (Central European Biotech Incubator and Accelerator) are collaborating to repurpose the antihistamine drug azelastine hydrochloride as a potential anti-SARS-CoV-2 therapeutic. Azelastine has been successfully used for many years in anti-allergic therapy.

Starting with a novel computational drug repurposing prediction method, developed and performed by Prof Dr Robert Konrat (University of Vienna), CEBINA selected already approved active substances for experimental testing in collaboration with Prof Dr. Ferenc Jakab (Virology National Laboratory, Szentágothai-Research-Center, University of Pécs, Hungary). This collaborative effort led to the identification of azelastine as a potent antiviral compound effective against SARS-CoV-2, a finding confirmed by now by several independent research groups. The potent anti-SARS-CoV-2 activity of azelastine was demonstrated in a reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available nasal sprays [1].

A clinical trial has started on February 16th 2021 to verify whether the use of a nasal spray preparation containing azelastine can achieve a reduction in viral load in the the nasal cavity. The aim of the study is to show whether the anti-allergic medication Pollival® Nasal Spray, or a diluted version, can achieve a reduction in the viral load, therefore reducing transmission and positively influencing the course of the disease.

If positive results of the running clinical studies are demonstrated, URSAPHARM Arzneimittel GmbH and CEBINA GmbH believe this will be an important new approach to control viral spread and contain the current pandemic.

SOURCE: EuropaWire

Curatronic Ltd. announces the new Ultra-Flash impulse PEMF device exceeding 1 Tesla

Jerusalem, Israel, 2021-Jan-28 — /EPR HEALTHCARE NEWS/ — The brand-new Curatron Ultra-Flash impulse PEMF machine for instantaneous pain relief.

Curatronic Ltd. announces to have started taking orders for their brand-new Curatron Ultra-Flash device completing the Curatron line of pulsed electromagnetic field therapy devices.

Curatronic Ltd. has succeeded in developing a completely service free, ultra-high intensity impulse PEMF device. The Curatron Ultra-Flash ultra-high intensity PEMF pulses are electronically controlled by high voltage solid state semiconductor game changing technology, without any need for service as required for obsolete spark gap technology.

The new Curatron Ultra-Flash has 10 internal computer-controlled programs offering a wide choice for various treatment possibilities. These built-in programs offer superior flexibility, including for use as ringer and oscillating applications of impulse PEMF.

Curatronic offers a wide range of PEMF models to choose from, according to individual needs. A wealth of information can be found on their website, both extensive technical information as well as practical applications.

Ben Philipson, CEO of Curatronic Ltd. said, “The amazing results for instantaneous pain relief have been experienced by me personally! Now that we have completed our line of impulse PEMF devices the new Curatron Ultra-Flash device excels in the ability to generate pulsed magnetic field levels exceeding the 10,000 Gauss barrier making all PEMF spark gap devices on the market obsolete. The new Ultra-Flash system is geared towards use by medical professionals and we are looking forward to start soon shipping to customers who have taken advantage of the large pre-order discount we offer.”

Further information can be found on the Curatronic website www.curatronic.com

Curatronic is the leading innovator in Pulsed Electromagnetic Field therapy. Founded in 2000, the company has clearly established itself as the undisputed leader in the field of PEMF therapy devices in 99 countries around the world.

Via EPR Network
More Healthcare press releases

American Hemp Processing To Roll Out Mobile Extraction Units

Sacramento, California, 2019-Dec-10 — /EPR HEALTHCARE NEWS/ — American Hemp Processing (AHP) is excited to announce the design completion of their Mobile Hemp Extraction Unit (MEHU). This is a key step in AHP’s expansion to increase production to 400,000lbs of hemp per month that will be completed 1st quarter 2020. The mobility of the MEHU reduces overall processing costs, mitigates many of the risks associated to transportation, and increases transparency with farmers.

The MHEU units bring significant benefits to the farmer from both a financial and risk mitigation perspective. “Most hemp farms are not close to processing facilities. Transportation is a large cost and increases the risk of degradation and contamination. On top of that, farmers still have to deal with legal issues in states that aren’t familiar with hemp and mistake it for marijuana,” says Andrew Alvarez Co-Founder and Chief Technology Officer “Additionally, it increases transparency with farmers and helps educate them along the way to build synergistic relationships”.

“The design of the MHEU was Phase 2 of our strategy,” says Shick Park Co-Founder and Chief Operations Officer, “Phase 1 was developing a scalable extraction and remediation process enabling us to create high quality and compliant CBD oil, and Phase 3 is the roll-out of the mobile extraction units on to farms fall of 2020.”

“This caps off a 12 month design process by our engineers and now we go to the assembly phase. These units will take approximately 120 days each to build, and we plan to initially build 3,” says Co-Founder and CEO Tom Richardson. “This has been a very rewarding journey for us, from meeting farmers all over the country, to government legislators, to fine tuning the extraction process, to meeting other processors and sharing ideas, we feel very confident about the Cannabinoid Sector business.”

Via EPR Network
More Healthcare press releases

Study published in World Journal of Urology confirms Fotona SMOOTH® laser technology is a safe, effective & minimally-invasive solution for stress and mixed urinary incontinence

LJUBLJANA, Slovenia, 21-Sep-2018 — /EPR HEALTHCARE NEWS/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further confirmation that Fotona SMOOTH® laser technology is a safe, effective and minimally-invasive solution for stress and mixed urinary incontinence (SUI and MUI). The article, written by Dr. Nobuo Okui, compares Fotona’s minimally invasive IncontiLase® Er:YAG laser therapy with the more conventional TVT and TOT surgical sling procedures.

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

In the study performed by Dr. Okui, 50 Japanese women were treated either surgically (tension-free vaginal tape – TVT or transobturator tape – TOT) or with a Fotona laser. The 1-h pad test, ICIQ-SF, and overactive bladder-symptom score were used to assess the patients before and 12 months after treatment. Laser therapy was performed by first applying a local anesthetic to the vaginal wall and then inserting a probe into the vagina. Laser irradiation was performed for 20 min with an Er:YAG wavelength of 2940 nm (Dynamis XS, Fotona) for a total of three treatments (alternating every month). Results of the 1-h pad test and ICIQ-SF showed comparable improvements in SUI in the sling and laser therapy groups, while some of the patients with MUI in the TVT and TOT groups showed exacerbation. In conclusion, the TVT and TOT procedures and the laser therapy are comparable for SUI; however, laser therapy is superior in terms of MUI and complications. The study thus once again confirms the safety and efficacy of Fotona SMOOTH® laser therapy for urinary incontinence.

Urinary Incontinence Treatment Options

Conventional treatment options for urinary incontinence are surgical, and include TVT or TOT sling procedures, which involve inserting a synthetic material. Problems often arise with artificial meshes that require new treatment methods. With the Fotona SMOOTH® Er:YAG laser thermotherapy (also known as IncontiLase®), the goal is to provide a minimally invasive therapy based on vaginal collagen hyperthermia followed by collagen remodeling and new collagen synthesis, which results in overall regeneration of aged or stressed vaginal tissues and subsequently greater support to the bladder.

Unique Fotona SMOOTH® Technology for Maximum Safety

Patient safety is the primary concern and, for this reason, the patented Fotona SMOOTH® technology holds a very unique position within the spectrum of gynecological treatment options. It is a non-surgical procedure (no incisions) and without implants or appliances. The Fotona SMOOTH® method of dual-tissue regeneration is completely non-ablative and therefore minimally invasive to the vaginal wall. The treatment involves an additional superficial heat-shocking mechanism of tissue regeneration, and a unique self-regulating safety feature. These dual-tissue regeneration characteristics of the Fotona SMOOTH® Er:YAG laser allow for an exceptionally high degree of safety and efficacy in thermotherapy of the vaginal wall. This is what makes Fotona SMOOTH® a significantly safer alternative to many widely used and more-invasive procedures.

Evidence-Based Laser Medicine

Over the past few years numerous (over 35) other studies on Fotona SMOOTH® laser therapy have been published by distinguished gynecologists from around the globe in some of the most trusted and renowned international scientific journals, all with favorable results (https://www.laserandhealthacademy.com/en/practitioners/recommended-reading/gynecology/). One such noteworthy clinical paper published in March 2018 by Dr. Adolf Lukanovic and Dr. Mija Blaganje is the first randomized controlled trial study (on 114 premenopausal parous women) to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy as an alternative non-invasive treatment of SUI and the improvement of sexual gratification (published in the European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 (224): 153-158). The results from this study indicate that a single session of IncontiLase® treatment improves the impact of SUI symptoms on quality of life and sexual function in premenopausal parous women significantly better than placebo.

In another Asian study, Dr. Yi-Wen Tien et al. from the Chang-Hua Hospital in Taiwan examined the effects of laser treatment for female SUI on pad weight, urodynamics, and sexual function in 35 women (published in the International Urogynecology Journal. 2017; 28(3): 469-476). The study reveals that the effect of IncontiLase® treatment for mild SUI was moderate at the 6-month follow-up. Moreover, it improved LUTS, quality of life, and the sexual function of both partners. The authors conclude that the IntimaLase® procedure is very effective in the treatment of SUI and is not associated with any severe adverse effects.

Similarly, Dr. Yi-Hao Lin et al. from the Chang Gung Memorial Hospital in Taiwan obtained favorable results. Their study investigated the effects of non-ablative laser treatment on overactive bladder (OAB) syndromes, SUI and sexual function in 30 women with urodynamic stress incontinence (published in the Taiwanese Journal of Obstetrics & Gynecology. 2017 (56): 815-820). The results showed that IncontiLase® treatment can resolve SUI and coexistent OAB symptoms three months after therapy, while repeated laser therapy may be necessary after six months. The results also revealed that sexual gratification improved, while no major adverse effects were noticed.

The quantity and quality of the studies performed with Fotona SMOOTH® laser therapy is such that Fotona’s Dynamis has been cleared in the European Union for SUI (IncontiLase®), vaginal laxity – vaginal relaxation syndrome (IntimaLase®), genitourinary syndrome of menopause – GSM (RenovaLase®) and pelvic organ prolapse (ProlapLase®), giving women the option to choose a safer and less-invasive treatment alternative. In Asia, the Taiwan Food and Drug Administration has already cleared Fotona Dynamis for mild to moderate SUI, and the Singapore Health Sciences Authority has cleared the Dynamis for the treatment of SUI and GSM.

SOURCE: EuropaWire

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Marrongelli selected for her expertise in Botanical Drug Development

LONDON, Jun-16-2018 — /EPR Healthcare News/ — As a leading expert in her field, Dr. Christina Marrongelli, PharmD has been chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference: Exploring New Trends & Innovations in Pharmacology and Natural Compounds. The conference is being held in Paris, France on June 18, 2018.

Dr. Marrongelli, who is an adjunct professor at the Medical University of South Carolina in the department of drug discovery and biomedical sciences will also present “Developing and Marketing Botanical Drugs in the United States”.

The United States, which has the largest pharmaceutical market in the world, demonstrates a strong demand for the use of botanicals as medicine. However, to date only two prescription botanical drugs are currently approved for use in the USA: Veregen® (sinecatechins) and Mytesi™Â (crofelemer).

Marrongelli attributes this disconnect between supply and demand to hidden barriers. She notes that with the worldwide herbal drug market is expected to reach nearly $86.74 billion by 2022, businesses must identify and address these barriers so that heterogeneous botanical drug products can obtain the approvals necessary to meet the consumers growing expectations and demands for botanical medicines.

To further explain the barriers to regulation of botanicals, Marrongelli points to the Botanical Drug Development Guidance for Industry from the U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) that was last updated in 2016. According to publication, regulation of botanicals in the U.S. is different from regulation in the rest of world. The U.S. does not have a separate regulatory category for traditional or herbal medicines: A botanical product may be classified as a food (including a dietary supplement), drug (including a biological drug), medical device, or cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Whether an article is a food, drug, medical device, or cosmetic depends in large part on its intended use.

To learn more about the issues and barriers to the development of botanical drugs, please contact Dr. Marrongelli at Marronge@musc.edu or DrM@pharmD.expert.

SOURCE: EuropaWire

Prof. Lucien Abenhaim: There is an incredible challenge for the sustainability of health systems across the world

Prof. Lucien Abenhaim

LONDON, Dec-3-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies.

The not-for-profit executive forum is organised by the London School of Hygiene and Tropical Medicine and analytica|LASER, a global research consultancy, to investigate topical questions around drug policy, global health systems sustainability and innovation funding through a combination of case studies, panel sessions, and roundtables. Delegations are registered from over 70 public and private organisations, including the World Health Organization, as well as health systems representatives from Belgium, England, Estonia, Croatia, France, Germany, Italy, Norway, Sweden, the United States and Wales. Multiple patient organisations support the meeting to ensure that the patient voice is reflected in all deliberations.

“Access to life-saving drugs is not a new challenge. The paradigm of accessibility was changed completely in the face of the deadly HIV epidemic. This time, however, accessibility concerns almost every domain of medicine such as cancer, auto-immune diseases and rare diseases. We must act now,” says Prof Peter Piot, Director of the London School of Hygiene & Tropical Medicine and former head of UNAIDS.

“There is an incredible challenge for the sustainability of health systems across the world”, says Prof. Lucien Abenhaim, London School of Hygiene & Tropical Medicine and Chairman of Analytica Laser. “It is critical that drug developers and health system engage on actionable proposals that address concerns around value, cost and overall access to innovation for the patients who need it. We are at an inflection point – the paradigms of the 1990’s can no longer guide us,” he adds.

The main plenary on December 6th features scheduled remarks by over a dozen authorities in the field, including Professor Baron Peter Piot (Director, London School of Hygiene & Tropical Medicine and former Head, UNAIDS), Dr. Olivier Brandicourt (Chief Executive Officer, Sanofi), Dr. Sarah Garner (World Health Organization), Prof. Dominique Le Guludec (President, French HAS), Sir Andrew Dillon (Chief Executive, National Institute for Health and Care Excellence UK) and Dr. Harold Paz (Chief Medical Officer, Aetna). The plenary is preceded by a scientific seminar on December 5th which gathers globally renowned academics to explore new frontiers on the methodology for the appraisal and valuation of high-value medicines.

Please contact the organisers for more information on the programming and media access, or refer to www.accessibility-symposium.org

SOURCE: EuropaWire

Connect. Integrate. Become One.

International Day of Yoga 21 June

Alpharetta, Georgia, US, 2017-Jun-13 — /EPR HEALTHCARE NEWS/ — The Heartfulness Institute will mark the International Day of Yoga on 21 June with public events in various locations globally (www.heartfulness.org). The events will be held at the Institute’s meditation and retreat centres and also at other community venues in partnership with civil society and yoga organizations and Indian diplomatic missions.

Every year on 21 June the United Nations invites the global community to celebrate the life-enhancing practices of Yoga. In establishing the International Day of Yoga, the United Nations underscored the need for building better lifestyles, recognizing that Yoga provides a holistic approach to health and well-being. The UN also called for the wider dissemination of information about the benefits of practising Yoga.

On the International Day of Yoga, the Heartfulness community, led by its youth, will bring together hundreds of thousands of people with the theme ‘Connect. Integrate. Become One’, in Chennai, Singapore, Hyderabad, Paris, New York, London, Toronto, Sydney and in other major metropolitan centres, as well as in many smaller cities, towns and rural areas globally. The core practices of Heartfulness are self-development tools for a modern lifestyle and for people from all walks of life. They include relaxation, heart-based meditation, cleaning and inner connection. There is no dogma or prerequisite of any kind, and no financial requirement; only the willingness and interest to try the simple, effective Heartfulness practices.

Since the beginning of 2017, the Heartfulness Institute has been offering free masterclasses in meditation, led by its global guide, Kamlesh Patel, also known as Daaji. More than one million people around the world, including educational, business and professional groups, have experienced the free masterclasses that are available at http://en.heartfulness.org/masterclass/.

Heartfulness is an approach to the Raja Yoga system of meditation called Sahaj Marg, founded at the turn of the 20th century and formalized into an organization in 1945. More than seventy years later, ongoing Heartfulness meditation training can be found at 2,500 schools and colleges, and over 100,000 professionals are meditating in over 3,000 corporations, non-governmental and government organizations.

Heartfulness Centres, known as HeartSpots, exist in 130 countries, supported by thousands of certified volunteer trainers. There are over 5,000 HeartSpots and over 300 retreat centres around the world where thousands of people gather to meditate (http://www.heartfulness.org/).

About Kamlesh D. Patel
Known to many as Daaji, Kamlesh D. Patel is the fourth guide in the Heartfulness tradition of meditation. He is a prolific speaker and writer, and you can read his latest writings at http://www.daaji.org/.

About Heartfulness Institute
Heartfulness Institute is a non-profit organization that promotes well-being and self-development through meditation, research and training. The Institute offers programs for individuals, local communities, corporates, government departments and the armed services, schools and colleges, rural communities and civil society groups worldwide, supported by certified trainers who are volunteers and who offer their time and expertise in this social cause.

For more information 
Email: info@heartfulness.org
Toll free numbers:India: 1-800-103-7726USA: 1-844-879-4327
Social Media: Heartfulness Facebook | Twitter | Google+ | YouTube | LinkedIN | Instagram

Websites: www.heartfulness.org, www.daaji.org
Durga Nagarajan, 180 Westchester Way, Alpharetta,Georgia 30005

Via EPR Network
More Healthcare press releases

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Sway Medical’s app for sports concussion exam received European CE Mark as Medical Device

sway-concussiontest-is-a-validated-ios-app-based-concussion-management-system

TULSA, OK, 08-Sep-2016 — /EPR HEALTHCARE NEWS/ — Sway Medical is a US medical device company who’s software turns an iPhone or iPad into a mobile medical device that provides immediate medical grade, objective concussion measurement to medical professionals.

Sway Medical LLC (Sway) would like to announce its official availability in all European Union Countries. Sway was issued its CE Mark after being marketed in the United States and Canada for two years. This is significant because European sports organizations ranging from youth through pro level now have an affordable and convenient sideline assessment tool supporting concussion related medical decision making. Medical professionals and trained coaches can obtain a concussion assessment via an Apple mobile device (iPhone or iPad) and the Sway Balanceâ„¢ System web-portal. Acute objective measurements are obtained by performing a 1.5 minute balance and reaction time test protocol. Licensed athletic trainers, physical therapists and athletic therapists are able to join physicians in acutely managing the underserved market of youth sports, ages six and older.

Concussion injuries are very common in sports, often going un-reported or ignored until the obvious symptoms have incapacitated the athlete or draws the attention of a parent or coach. Second Impact Syndrome (SIS) is a serious medical condition with published mortality rates of up to 50%. SIS occurs when an athlete returns to play while still recovering from an initial concussion injury. During this time, the brain is highly susceptible to additional injury and complications. The Sway Balance™ System is able to accurately assess and track the acute and chronic outcome related to an athlete’s balance, motion reaction time and concussion symptoms. The Sway Balance™ System provides a graphical representation comparing suspicious injury event tests against a pre-injury “normative” or baseline score. The comparison of event tests against an established baseline is a common measurement for traumatic brain injury diagnosis and recovery tracking.

The Sway Balance™ System is available for purchase by licensed medical professionals involved in school, occupational or sports medicine through www.swaymedical.com. Additional protocols are available to assess an individual’s “Fall Risk” or “Functional Status”.

SOURCE: EuropaWire

TESTmyBRAIN opens its first center of Functional Neurology in Europe

GENEVA, 2016-Jun-8 — /EPR Healthcare News/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … all disorders related to the brain and the central nervous system.

This innovative therapy combines several approaches and relies mainly over 3 decades of research on the eye-movements to diagnose and treat. Completely adopted and established in the United States, this therapy is almost unknown in Europe.

This is the reason why TESTmyBRAIN Switzerland is happy to bring the American experts to Europe to teach other doctors and to help patients differently with their pain.

SOURCE: EuropaWire

Regenexx Announces the Publication of “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” on Amazon Kindle

Broomfield, CO, February 02, 2015 — /EPR HEALTHCARE NEWS/ — With more than 40,000 downloads, “Orthopedics 2.0 – How Regenerative Medicine and Interventional Orthopedics will Change Everything” is now available on Amazon Kindle. The third edition of the top-selling e-book is being offered as a free download through Jan. 6, 2015.

Written by Dr. Chris Centeno, this e-book delves into the human musculoskeletal system and explains how everything works together in concert to maintain our physical wellbeing. When a single component in this chain is damaged, it can lead to a cascade of joint, spine and connective tissue problems, resulting in chronic pain.

Using the Regenexx SANS approach, Orthopedics 2.0 walks you through a series of tests and exercises that you can do on your own to better understand where your own body is struggling to maintain proper stability and alignment, explaining the possible reasons and long term implications along the way. Orthopedics 2.0 also explores how Regenexx is pioneering the new field of Interventional Orthopedics, where the use of regenerative biologic treatments, such as adult stem cell therapy and platelet rich plasma, are being used to help repair and strengthen damaged tissues, as opposed to invasive surgeries that often remove important tissues when a joint or the spine becomes damaged.

With hyperlinks to more detailed information, related studies and commentary, this book condenses a vast amount of data and resources into an enjoyable and entertaining read.

About Regenexx
Since its genesis in 2005, Regenexx has been a world-leader in the use of adult stem cell treatments for orthopedic conditions, providing non-surgical, biologic therapies delivered with high accuracy through a needle. Regenexx has collected and published more data on stem cell patients than any other company and are dedicated to reinventing orthopedic care to help patients avoid invasive surgery.

Featured on television and media outlets such as the Doctors TV show, ABC News, Good Morning America and many others, Regenexx is taking orthopedic stem cell therapy to an exciting new level.

For more information about this e-book or to talk with a Regenexx Liaison, please call 888-525-3005 or email info@regenexx.com. Visit Regenexx online at:http://www.regenexx.com/

Contact-Details: Regenexx
Contact: Mark Testa
403 Summit Blvd., Suite 201
Broomfield, CO 80021
Phone: 888.525.3005
Email: info@regenexx.com
Web – http://www.regenexx.com/

Via EPR Network
More Healthcare press releases

Aging and Genes: Nutrition is Key

Each year, millions of Americans die of preventable, often chronic disease. This happens because people believe disease is caused by things they can’t control: inherited genes or aging. Neither is true. Health experts know that about 80% of health status is determined by daily choices and gene activity, not inherited genes or age.

Most genes are active day and night. They respond to many activities, especially nutrition. Other areas play a role, including, exercise, stress, weight and inflammation. In fact, it’s normal to replace about 1 billion cells every hour, and over time, that complex process of cell division can cause mutations and errors. What’s more, those risks are markedly increased by an unhealthy lifestyle.

A new, breakthrough article called, “Telomeres Genes and Aging” explores these critical issues and includes the latest research. The article includes critical “how to” tips to prevent chronic disease and improve longevity! It’s based on more than 50 credible source links, including numerous studies and expert sources. Some key findings are:

1. Nutrition and micro-nutrient intakes (vitamins, minerals, antioxidants) are key factors for gene activation and repair, including telomere length and longevity.

2. Other lifestyle areas contribute to gene health, including weight status, sleep, stress, activity, etc., and they all contribute to gene function, replication and repair.

3. Sirtuin proteins also help to activate or silence genes, especially those for metabolism, stress response, brain function, longevity, etc. Sirtuins are also enhanced by nutrient intake and harmed by nutrient deficiencies.

There is now enough research to show how to maximize gene health and replication, including telomere length, health and longevity. By making the right choices, gene health can be maximized, including the repair of mutations and genetic errors. Humans can largely control their health and destiny today!

Here is a link to the full article and source links:

http://www.endsicknessnow.com/telomeres-genes-and-aging

Contact: Steve Carney
steve@endsicknessnow.com
Twitter: @healthdietcoach

Via EPR Network
More Healthcare press releases

Heavenly Spa Set to Follow Up the Success of their ‘Colonic Irrigation’ YouTube Video with a New Video Promoting their London Spa

Having already found success with their ‘Colonic Irrigation London & Colonic Irrigation Information’ YouTube Video, Heavenly Spa are Soon to Launch a New Video Showing the Many Other Treatments that their Central London Spa Offers.

Nine months after their colonic irrigation video’s release on YouTube and over 8,000 views later, Heavenly Spa are in the later stages of production for a new video that showcases their spa and the many treatments that they offer. Their idyllic spa is located just a short two minute walk from Paddington Underground Station in London, tucked away in a quiet, discreet mews.

“We offer our clients the ultimate in relaxation and rejuvenation.” says Heavenly Spa owner Marlin Armstrong. “We are in such a great location what with Paddington being just two minutes away, but the lovely mews that we’re in allows our clients to be transported away from the hustle and bustle of London and into our calming retreat – we even have a dedicated relaxation room to allow our clients to unwind before and after their treatments.”

The spa and its fully trained beauty therapists are the leaders in colonic irrigation. “The spa is built on the ethos of “beauty starts from within” and our colonic treatment promotes complete well-being from the inside out” explains Marlin. Their treatment comes recommended by Elle Magazine who said their colonic hydrotherapy treatment was “A whole lot easier than previous experiences.”

Priding themselves on providing the client with the most discreet, unobtrusive and comfortable colonic irrigation possible, Heavenly Spa uses the most advanced and medically approved colonics system. “Once clients understand the process, they are able to relax and enjoy their colonic.” says Marlin.

Colonic hydrotherapy works by using warm, filtered water to loosen faecal matter and stimulate its release. “This process allows the bowel to hydrate, cleanse, detoxify and tone internally.” explains Marlin. “A colonic irrigation can result in reduced bloating and a stronger immune system. It can also be highly beneficial for those suffering with constipation and irritable bowel syndrome – though we do recommend a course of treatment if this is case.”

Their clients can either opt for a one off treatment, a course of treatments or colonic irrigation can form part of a bespoke well-being package, specifically designed to achieve clear, long lasting results for the client.

Heavenly Spa has many relaxation therapies and facilities, such as an exercise pool and gym, an infra red deep-heat absorption sauna and massage treatments. “Upon speaking with our clients and gauging what results they want, we can design a tailor-made treatment plan to get them to their goal and achieve long lasting results.” says Marlin.

With a new online video in the pipeline, Marlin hopes that viewers will be able to get a sense of their blissful spa. “Heavenly Spa is specially designed to amplify natural daylight and it is filled with purified air. Our colonic irrigation video does show our spa and its natural architecture and relaxing vibe. It has been such a success so we wanted to release another video that goes into more depth about the other treatments and therapies we offer here.”

To see their colonic irrigation video, follow this link https://www.youtube.com/watch?v=t-U9xGepDJ8 or visit their website at http://www.heavenlyspa.co.uk.

Via EPR Network
More Healthcare press releases

Stretch Physio Launches New Online Yoga Photo Competition

The Chelmsford-based physiotherapy clinic has launched a brand new social media competition in conjunction with sister company The Hummingbird Centre.

The competition was inspired by a photo the team received via Twitter from Alison Fuller, who captured her foreign adventures on camera by striking a lotus pose while taking a break on the Bolivian Salt Flats in Uyuni. This beautifully striking picture captured the imagination of the owners of Stretch Physio and neighbour The Hummingbird Centre. The team is now asking for more travellers to get in touch with photos of themselves doing yoga or Pilates around the world.

The owner of each photo received will then be put into the draw to win an amazing prize with the company’s Directors. The prize includes a physiotherapy session with Ellie Searle, specialist physiotherapist and Director of Stretch and The Hummingbird Centre, a one-to-one Pilates session with Kellie Jones, Director of The Hummingbird Centre, experienced Pilates teacher and general Pilates and yoga guru, and an en vogue hot yoga class, which will be coming soon to the Centre.

Facebook fans have responded well to the launch of the competition and the team at Stretch and The Hummingbird Centre have received some stunning entries to date.

The two centres decided to launch a joint competition to better promote the wide range of classes and treatments offered at The Hummingbird Centre.

“Naturally, we wanted to use the contest to raise awareness of our business in the local area, but we also wanted to get our online audience more involved in what we do by incentivising them to share their imagery and experiences,” says Ellie Searle.

“Myself and my business partner Kellie both believe that a picture speaks a thousand words. We think that these beautiful photos encapsulate the soothing and calming effects that regular yoga or Pilates can have on an individual. We hope these images will inspire many of our followers to give yoga or Pilates a try at the Centre in order to fully understand why so many people consider these practices to be such an integral part of their overall health and wellbeing.”

Those interested in entering the contest are encouraged to visit The Hummingbird Centre’s Facebook page for entry details. The winner will be announced on 5th January 2014, but participants are encouraged to refer back to the company’s social media profiles for updates, special offers and future competitions.

Stretch Physiotherapy & Pilates is based at The Hummingbird Centre, a specialist Pilates and yoga centre in Chelmsford. Stretch Physiotherapy & Pilates offers a wide range of musculoskeletal physiotherapy expertise in their well equipped private clinic. In addition to offering physiotherapy, the team also offer massage treatments, acupuncture and one-to-one Pilates training. More information can be found at http://www.stretchphysio.co.ukand http://www.hummingbirdpilates.co.uk.

Via EPR Network
More Healthcare press releases

Gift Vouchers Now Available From The Hummingbird Centre In Essex

The Essex-based Yoga and Pilates centre is kick-starting the New Year by promoting its in-house gift vouchers, which can also be redeemed with its in house physiotherapy and massage clinic, Stretch Physiotherapy.

The gift vouchers now available from The Hummingbird Centre make a great New Year pick-me-up for that special someone. As the company itself states in its most recent newsletter, January is the ideal time of year to ‘give some goodwill to yourselves’, especially after such a hectic Christmas period. Let the team help you to feel better this New Year and work with you to achieve your health and fitness goals.

The vouchers make an excellent gift as they can be redeemed against yoga and Pilates classes at The Hummingbird Centre. The Centre also offers one-to-one Pilates sessions with the company’s founders Ellie Searle and Kellie Jones. Ellie offers specialist skills as both a Physiotherapist and Pilates instructor and can therefore tailor a programme for those who are recovering from illness or injury, as well as those looking to improve their sporting performance with a bespoke Pilates exercise programme. Kellie is an experienced Pilates teacher, with her wealth of experience and extensive repertoire of exercises, she often uses the reformer and other Pilates equipment to help her clients get into their best possible shape.

Lucky recipients can also use their vouchers against physiotherapy or massage treatment at the Stretch clinic. Stretch has a team of specialist physiotherapists and massage therapists, with a wide range of experience and hands on skills, so whatever your problem, the team should be able to help.

Purchase a voucher and book a holistic massage with one of the company’s trained and experienced massage therapists. Those looking for a rejuvenating treatment may be inclined to try out a Swedish tissue massage, which releases chronic muscle tension, while those who train regularly may prefer to organise an appointment with resident sports massage specialist Mark Laybourn, who has been working in the field for over ten years, helping people to recover from sports injuries or to prepare for a competition.

Ellie Searle, founder of Stretch Physiotherapy, explains why she and the rest of the team at The Hummingbird Centre expect to see a reasonable increase in bookings now that the Christmas season is well and truly over.

“At this time of year most of us are in desperate need of some ‘me’ time after a busy Christmas and New Year period. “This is traditionally the time of year when we receive a lot of enquiries from people who have decided that this year they are going to take some time out to look after themselves either to deal with a specific injury or to get in shape.”

Those interested in purchasing gift vouchers from The Hummingbird Centre are encouraged to call 01245 422556. To discover more about the Hummingbird Centre visit the website atwww.humminbirdpilates.co.uk. To find out more about Physiotherapy and massage treatments visit the Stretch Physiotherapy website at http://www.stretchphysio.co.uk.

Via EPR Network
More Healthcare press releases